Skip to main content
SpringerLink
Log in
Book cover

Metastasis of Prostate Cancer pp 309–335Cite as

Strategies for the Implementation of Chemotherapy and Radiotherapy

  • Chapter

  • 671 Accesses

Part of the book series: Cancer Metastasis – Biology and Treatment ((CMBT,volume 10))

Abstract

The traditional roles of cytotoxic chemotherapy and radiotherapy in metastatic prostate cancer have been in the palliation of symptoms of the disease. Two recent phase 3 randomised controlled trials have demonstrated for the first time a survival benefit for men with metastatic hormone refractory prostate cancer treated with decotaxel and steroids. This has generated a remened interest in the systemic management of the disease.

This chapter describes the evolution of the role of cytotoxic chemotherapy for patients with hormone refactory prostate cancer, from the early studies demonstrating improved symptom control, to a discussion on novel agents currenthy under investigation.

The role of ionising radiation therapy, both external beam radio therapy and bone - seeking radio nuclide therapy, in the palliation of disease related symptom particularly bone pain is also discussed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   179.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Eisenberger MA, Simon R, O’Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985, 3:827–41.

    PubMed  CAS  Google Scholar 

  2. Figg WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N et al. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 1996, 14:513–7.

    Article  PubMed  CAS  Google Scholar 

  3. Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol 1984, 142:773–6.

    PubMed  CAS  Google Scholar 

  4. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. J Clin Oncol 1999, 17:3461–7.

    PubMed  CAS  Google Scholar 

  5. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17:2506–13.

    PubMed  CAS  Google Scholar 

  6. Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 1992, 70:2870–8.

    Article  PubMed  CAS  Google Scholar 

  7. La Rocca RV, Danesi R, Cooper MR, Jamis-Dow CA, Ewing MW, Linehan WM et al. Effect of suramin on human prostate cancer cells in vitro. J Urol 1991, 145:393–8.

    PubMed  Google Scholar 

  8. Rago R, Mitchen J, Cheng AL, Oberley T, Wilding G. Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism. Cancer Res 1991, 51:6629–35.

    PubMed  CAS  Google Scholar 

  9. Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A, Larsen AK. Suramin is an inhibitor of DNA topoisomerase II in vitro and in chinese hamster fibrosarcoma cells. Proc Natl Acad Sci U S A 1992, 89:3025–9.

    Article  PubMed  CAS  Google Scholar 

  10. Hartley-Asp B, Gunnarsson PO. Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145). J Urol 1982, 127:818–22.

    PubMed  CAS  Google Scholar 

  11. Stearns ME, Tew KD. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res 1985, 45:3891–7.

    PubMed  CAS  Google Scholar 

  12. Petrylak DP, Macarthur RB, O’Connor J, Shelton G, Judge T, Balog J et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999, 17:958–67.

    PubMed  CAS  Google Scholar 

  13. Hernes EH, Fossa SD, Vaage S, Ogreid P, Heilo A, Paus E. Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: A phase II study. Br J Cancer 1997, 76:93–9.

    PubMed  CAS  Google Scholar 

  14. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997, 15:3156–63.

    PubMed  CAS  Google Scholar 

  15. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001, 19:2509–16.

    Google Scholar 

  16. Smith DC, Pienta KJ. Paclitaxel in the treatment of hormone-refractory prostate cancer. Semin Oncol 1999, 26(Suppl 2):109–1.

    PubMed  CAS  Google Scholar 

  17. Colleoni M, Graiff C, Vicario G, Nelli P, Sgarbossa G, Pancheri F et al. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Am J Clin Oncol 1997, 20:383–6.

    Article  PubMed  CAS  Google Scholar 

  18. Amato RJEJ, Bui C, Logothetis CJ. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol Semin Orig Invest 1995, 1:168–172.

    Article  Google Scholar 

  19. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998, 16:1835–43.

    PubMed  CAS  Google Scholar 

  20. Smith PH, Suciu S, Robinson MR, Richards B, Bastable JR, Glashan RW et al. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: Final analysis of a phase III trial of the european organization for research on treatment of cancer. J Urol 1986, 136:619–23.

    PubMed  CAS  Google Scholar 

  21. Hedlund PO, Jacobsson H, Vaage S, Hahne B, Sandin T, Kontturi M et al. Treatment of high-grade, high-stage prostate cancer with estramustine phosphate or diethylstilbestrol. A double-blind study. The SPCG-1 study group. Scandinavian prostate cancer group. Scand J Urol Nephrol 1997, 31:167–72.

    Article  PubMed  CAS  Google Scholar 

  22. Hedlund PO, Gustafson H, Sjogren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (estracyt) or conventional estrogen. A follow-up of 212 randomized patients. Scand J Urol Nephrol Suppl 1980, 55:103–5.

    PubMed  CAS  Google Scholar 

  23. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al. With mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A canadian randomized trial with palliative end points. Chemotherapy 1996, 14:1756–64.

    CAS  Google Scholar 

  24. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000, 18:1440–50.

    PubMed  CAS  Google Scholar 

  25. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502–2.

    Article  PubMed  CAS  Google Scholar 

  26. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513–20.

    Article  PubMed  CAS  Google Scholar 

  27. Dowling AJ, Czaykowski PM, Krahn MD, Moore MJ, Tannock IF. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: Prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol 2000, 163:1481–5.

    Article  PubMed  CAS  Google Scholar 

  28. De Reijke TM, Keuppens FI, Whelan P, Kliment J, Robinson MR, Rea LA et al. De. J Urol 1999, 162:1658–64; discussion, 1664–5.

    Google Scholar 

  29. Osborne CK, Blumenstein B, Crawford ED, Coltman CA Jr, Smith AY, Lambuth BW et al. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized southwest oncology group study. J Clin Oncol 1990, 8:1675–82.

    PubMed  CAS  Google Scholar 

  30. Fontana D, Bertetto O, Fasolis G, Berruti A, Tarabuzzi R, Pagani G et al. Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 1998, 84:39–44.

    PubMed  CAS  Google Scholar 

  31. Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997, 32:81–5.

    PubMed  CAS  Google Scholar 

  32. Janknegt RA, Boon TA, van de Beek C, Grob P. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The dutch estracyt study group. Urology 1997, 49:411–20.

    Article  PubMed  CAS  Google Scholar 

  33. Boel K, Van Poppel H, Goethuys H, Derluyn J, Vandenbroucke F, Popelier G et al. Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 1999, 19(3B):2157–61.

    PubMed  CAS  Google Scholar 

  34. Miyake H, Hara I, Fujisawa M, Eto H, Okada H, Arakawa S et al. Comparison of hormonal therapy and chemohormonal therapy in patients with newly diagnosed clinical stage D prostatic cancer. Int J Urol 1996, 3:472–7.

    Article  PubMed  CAS  Google Scholar 

  35. James PN. PRO8: STAMPEDE – Systemic therapy in advancing or metastatic prostate cancer: Evaluation of drug efficacy. 11/09/2006 [Cited].

    Google Scholar 

  36. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005, 23:1439–46.

    Article  PubMed  CAS  Google Scholar 

  37. Hussain M, Tangen CM, Lara PN Jr, Vaishampayan UN, Petrylak DP, Colevas AD et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A southwest oncology group trial S0111. J Clin Oncol 2005, 23:8724–9.

    Article  PubMed  Google Scholar 

  38. Lee D. Activity of epothilone B analogues ixabepilone and patupilone in hormone-refractory prostate cancer. Clin Prostate Cancer 2004, 3(2):80–2.

    PubMed  Google Scholar 

  39. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. Prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005, 68:2–9.

    Article  PubMed  CAS  Google Scholar 

  40. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998, 78:940–4.

    PubMed  CAS  Google Scholar 

  41. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999, 54:523–7.

    Article  PubMed  CAS  Google Scholar 

  42. Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999, 161:960–3.

    Article  PubMed  CAS  Google Scholar 

  43. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001, 7:1888–93.

    PubMed  CAS  Google Scholar 

  44. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2532–9.

    Article  PubMed  CAS  Google Scholar 

  45. Picus JHS, Rini B, Vogelzang N, Whang Y, Kaplan E, Kelly W, Small E. 2003,:. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. In: ASCO Annual Meeting; 2003: Proc Am Soc Clin Oncol; 2003.

    Google Scholar 

  46. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995, 1:944–9.

    Article  PubMed  CAS  Google Scholar 

  47. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996, 56:663–8.

    PubMed  CAS  Google Scholar 

  48. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial. J Clin Oncol 2003, 21:679–89.

    Article  PubMed  CAS  Google Scholar 

  49. Nilsson S, Reubi JC, Kalkner KM, Laissue JA, Horisberger U, Olerud C et al. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111in]-labeled DTPA-D-[PHE1]-octreotide scintigraphy. Cancer Res 1995, 55(23 Suppl):5805s–10s.

    PubMed  CAS  Google Scholar 

  50. Kalkner KM, Nilsson S, Westlin JE. [111in-DTPA-D-PHE1]-octreotide scintigraphy in patients with hormone-refractory prostatic adenocarcinoma can predict therapy outcome with octreotide treatment: A pilot study. Anticancer Res 1998, 18(1B):513–6.

    PubMed  CAS  Google Scholar 

  51. Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res 1998, 58:4132–7.

    PubMed  CAS  Google Scholar 

  52. Small EJSPF, Higano CS, Neumanaitis J, Valone F, Hershberg R. 2005, Results of a Placebo-Controlled Phase III Trial of Immunotherapy with APC8015for Patients with Hormone Refractory Prostate Cancer (HRPC). In: ASCO Annual Meeting; 2005 June 1: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings; 2005. p. 4500.

    Google Scholar 

  53. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006, 12:1260–9.

    Article  PubMed  CAS  Google Scholar 

  54. Arcangeli G, Micheli A, Giannarelli D, La Pasta O, Tollis A, Vitullo A et al. The responsiveness of bone metastases to radiotherapy: The effect of site, histology and radiation dose on pain relief. Radiother Oncol 1989, 14:95–101.

    Article  PubMed  CAS  Google Scholar 

  55. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: Final results of the study by the radiation therapy oncology group. Cancer 1982, 50:893–9.

    Article  PubMed  CAS  Google Scholar 

  56. Huddart RA, Rajan B, Law M, Meyer L, Dearnaley DP. Spinal cord compression in prostate cancer: Treatment outcome and prognostic factors. Radiother Oncol 1997, 44:229–36.

    Article  PubMed  CAS  Google Scholar 

  57. Schultheiss TE. Spinal cord radiation tolerance. Int J Radiat Oncol Biol Phys 1994, 30:735–6.

    PubMed  CAS  Google Scholar 

  58. Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: A global analysis of the dutch bone metastasis study. Radiother Oncol 1999, 52:101–9.

    Article  PubMed  CAS  Google Scholar 

  59. Gaze MN, Kelly CG, Kerr GR, Cull A, Cowie VJ, Gregor A et al. Relief and quality of life following radiotherapy for bone metastases: A randomised trial of two fractionation schedules. Pain 1997, 45:109–6.

    CAS  Google Scholar 

  60. Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 1998, 47:233–40.

    Article  PubMed  CAS  Google Scholar 

  61. Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986, 6:247–55.

    Article  PubMed  CAS  Google Scholar 

  62. Hoskin PJ, Price P, Easton D, Regan J, Austin D, Palmer S et al. A prospective randomised trial of 4 gy or 8 gy single doses in the treatment of metastatic bone pain. Radiother Oncol 1992, 23:74–8.

    Article  PubMed  CAS  Google Scholar 

  63. Blitzer PH. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 1985, 55:1468–72.

    Article  PubMed  CAS  Google Scholar 

  64. Chow E, Danjoux C, Wong R, Szumacher E, Franssen E, Fung K et al. Palliation of bone metastases: A survey of patterns of practice among canadian radiation oncologists. Radiother Oncol 2000, 56:305–14.

    Article  PubMed  CAS  Google Scholar 

  65. Roos DE. Continuing reluctance to use single fractions of radiotherapy for metastatic bone pain: An australian and new zealand practice survey and literature review. Radiother Oncol 2000, 56:315–22.

    Article  PubMed  CAS  Google Scholar 

  66. Lievens Y, Kesteloot K, Rijnders A, Kutcher G, Van den Bogaert W. Differences in palliative radiotherapy for bone metastases within western european countries. Radiother Oncol 2000, 56:297–303.

    Article  PubMed  CAS  Google Scholar 

  67. Dearnaley DP, Bayly RJ, A’Hern RP, Gadd J, Zivanovic MM, Lewington VJ. Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89. Clin Oncol (R Coll Radiol) 1992, 4:101–7.

    CAS  Google Scholar 

  68. Hoskin PJ, Ford HT, Harmer CL. Hemibody irradiation (HBI) for metastatic bone pain in two histologically distinct groups of patients. Clin Oncol (R Coll Radiol) 1989, 1:67–9.

    CAS  Google Scholar 

  69. Salazar OM, Rubin P, Hendrickson FR, Poulter C, Zagars G, Feldman MI et al. Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: A preliminary report. Int J Radiat Oncol Biol Phys 1981, 7:773–81.

    PubMed  CAS  Google Scholar 

  70. Lewington VJ. Therapy using bone-seeking isotopes. Cancer 1996, 41(10):2027–42.

    CAS  Google Scholar 

  71. Porter AT, Davis LP. Systemic radionuclide therapy of bone metastases with strontium-89. Oncology (Williston Park) 1994, 8:93–6; discussion 96, 99–101.

    Google Scholar 

  72. Mertens WC, Stitt L, Porter AT. Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: A dose response relationship. Am J Clin Oncol 1993, 16:238–42.

    Article  PubMed  CAS  Google Scholar 

  73. McEwan AJ, Amyotte GA, McGowan DG, MacGillivray JA, Porter AT. A retrospective analysis of the cost effectiveness of treatment with metastron (89sr-chloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun 1994, 15:499–504.

    Article  PubMed  CAS  Google Scholar 

  74. Malmberg I, Persson U, Ask A, Tennvall J, Abrahamsson PA. Painful bone metastases in hormone-refractory prostate cancer: Economic costs of strontium-89 and/or external radiotherapy. Urology 1997, 50:747–53.

    Article  PubMed  CAS  Google Scholar 

  75. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991, 27:954–8.

    Article  PubMed  CAS  Google Scholar 

  76. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994, 31:33–40.

    Article  PubMed  CAS  Google Scholar 

  77. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H et al. Results of randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993, 25:805–13.

    PubMed  CAS  Google Scholar 

  78. Maxon HR, 3rd, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R et al. Rhenium-186(sn)HEDP for treatment of painful osseous metastases: Results of a double-blind crossover comparison with placebo. J Nucl Med 1991, 32:1877–81.

    PubMed  Google Scholar 

  79. O’Sullivan JM, McCready VR, Flux G, Norman AR, Buffa FM, Chittenden S et al. High activity rhenium-186 HEDP with autologous peripheral blood stem cell rescue: A phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 2002, 86:1715–20.

    Article  PubMed  CAS  Google Scholar 

  80. Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simon J, Wilson D. Skeletal localization of samarium-153 chelates: Potential therapeutic bone agents. J Nucl Med 1987, 28:495–504.

    PubMed  Google Scholar 

  81. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R et al. A dose-controlled study of 153sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997, 33:1583–91.

    Article  PubMed  CAS  Google Scholar 

  82. Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G et al. Effects of low-dose cisplatin on 89sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial. J Nucl Med 2002, 43:79–86.

    PubMed  CAS  Google Scholar 

  83. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 2001, 357:336–41.

    Article  PubMed  CAS  Google Scholar 

  84. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001, 12:1273–9.

    Article  PubMed  CAS  Google Scholar 

  85. Brausi M, Jones WG, Fossa SD, de Mulder PH, Droz JP, Lentz MA et al. High dose epirubicin is effective in measurable metastatic prostate cancer: A phase II study of the EORTC genitourinary group. Eur J Cancer 1995, 31A:1622–6.

    Article  PubMed  CAS  Google Scholar 

  86. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group. Cancer 1993, 72:2457–60.

    Article  PubMed  CAS  Google Scholar 

  87. Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 1995, 76:453–62.

    Article  PubMed  CAS  Google Scholar 

  88. Oudard S, Caty A, Humblet Y, Beauduin M, Suc E, Piccart M et al. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol 2001, 12:847–52.

    Article  PubMed  CAS  Google Scholar 

  89. Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ. The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: Observations on the design of clinical trials for androgen-independent prostate cancer. J Urol 1995, 153:1587–91.

    Article  PubMed  CAS  Google Scholar 

  90. Huan SD, Stewart DJ, Aitken SE, Segal R, Yau JC. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am J Clin Oncol 1999, 22:471–4.

    Article  PubMed  CAS  Google Scholar 

  91. Smith MR, Kaufman D, Oh W, Guerin K, Seiden M, Makatsoris T et al. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: A phase II study. Cancer 2000, 89:1824–8.

    Article  PubMed  CAS  Google Scholar 

  92. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999, 17:1664–71.

    PubMed  CAS  Google Scholar 

  93. Pienta KJ, Fisher EI, Eisenberger MA, Mills GM, Goodwin JW, Jones JA et al. A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A southwest oncology group trial (SWOG 9407). Prostate 2001, 46:257–61.

    Article  PubMed  CAS  Google Scholar 

  94. Francini G, Petrioli R, Manganelli A, Cintorino M, Marsili S, Aquino A et al. Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 1993, 67:1430–6.

    PubMed  CAS  Google Scholar 

  95. Albrecht W, Van Poppel H, Horenblas S, Mickisch G, Horwich A, Serretta V et al. Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer 2004, 90:100–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northern Ireland Cancer Centre and Queen’s University Belfast, Belfast, Northern Ireland, UK

    Paula Scullin & Joe M. O’Sullivan

  2. Unit of Academic Urology, Institute of Cancer Research/Royal Marsden NHS Trust, Sutton, Surrey, UK

    Christopher C. Parker

Authors
  1. Paula Scullin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joe M. O’Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher C. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Arizona College of Medicine, and the Arizona Cancer Center, Tucson, AZ, U.S.A

    Richard J. Ablin

  2. University of Cardiff, U.K

    Malcolm D. Mason

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Scullin, P., O’Sullivan, J.M., Parker, C.C. (2008). Strategies for the Implementation of Chemotherapy and Radiotherapy. In: Ablin, R.J., Mason, M.D. (eds) Metastasis of Prostate Cancer. Cancer Metastasis – Biology and Treatment, vol 10. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5847-9_14

Download citation

Publish with us

Policies and ethics

Search

Navigation